Ainos (AIMD) Issues Mid-Year Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Ainos Issues Mid-Year Update: Reaching Strategic Inflection in SmellTech and Immunotherapy
June 16, 2025 8:01 AM EDTAI Nose Platform Advances Toward Scaled Pilot Programs Across Healthcare, Robotics, and Industrials
VELDONA® Oral Interferon Receives Approval to Begin Human Trials in Taiwan
SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Ainos, Inc. (NASDAQ: AIMD)(NASDAQ: AIMDW) ("Ainos" or the "Company") today issued a mid-year update outlining key strategic milestones achieved during the first half of 2025. The Company has transitioned from R&D to commercial execution, marked by its first AI Nose-driven... More
